Since the disappointment of the Phase III MYSTIC trial failure earlier this year,...
- AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
- Acticor Biotech to assess ACT017 in Phase I trial
- Tenapanor likely to makes waves in IBS-C space
- Why are over half of newly-approved cancer drugs failing to deliver?
- Anacetrapib failure marks the death of the CETP class of cholesterol-lowering therapies
AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
Since the disappointment of the Phase III MYSTIC trial failure earlier this year, AstraZeneca has redirected its efforts in non-small cell lung cancer to gaining approval in the second-line and maintenance settings.
Tenapanor likely to makes waves in IBS-C space
On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety of its lead product, tenapanor, which is under development for treatment of irritable bowel syndrome with constipation.
Why are over half of newly-approved cancer drugs failing to deliver?
A recent study has found that only 43% of cancer drugs recently approved in Europe allowed patients to live longer, or improved their quality of life.
Anacetrapib failure marks the death of the CETP class of cholesterol-lowering therapies
Merck & Co recently decided not to apply for regulatory approval of anacetrapib, one of the last-standing drugs from the doomed cholesteryl ester transfer protein (CETP) class of cholesterol-lowering therapies.
Could a new gene-editing technology permanently cure Duchenne muscular dystrophy?
Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR gene-editing technology inside cells, and have demonstrated in mice that it can repair the faulty gene mutation that causes the severe muscle-wasting disease Duchenne muscular dystrophy.
Asia-Pacific: the rising region for cancer vaccine clinical trials
An analysis was conducted by GlobalData into the regions with the highest number of cancer vaccine clinical trials initiated between 2007 and 2016.
Industry trials were more frequent than non-industry trials from 2012 – 2016
As part of our series of white papers tracking clinical trials activity around the world, GlobalData recently compiled a summary of clinical trial in Australia.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.